Neurochem's 2nd-qtr losses up 9%

27 August 2006

Canadian drugmaker Neurochem says that it suffered a net loss of C$20.4 million ($18.2 million), or $0.53 per share, for the second quarter ended June 30, 2006. The firm said that the increased loss, up 9.1% on the comparable period last year, was due to its higher R&D costs relating to ongoing European and US Phase III assessment of the developmental Alzheimer's disease treatment Alzhemed (tramiprosate).

Neurochem also reported that, as of June 30, its cash, cash equivalents and marketable securities stood at C$41.9 million, a drop of some 41.1% from December 31 last year. The firm attributed the decrease to increased operational costs, but added that the decline had been partially offset by the C$9.1 million in proceeds it received following fellow Canadian company Picchio Pharma's decision to exercise a 2003 warrant entitlement earlier this year (Marketletter February 27).

Establishes $60M securities purchase deal

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight